Clinical Trials Logo
  1. Home
  2. Rotavirus Infections
  3. NCT00443846

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Meningitis, Meningococcal Clinical Trial

Official title:
An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants

Clinical Trial Summary

Primary objective:

To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine without impairing the efficacy of MCC vaccine. The hypothesis tested is that the seroprotection rate for MMC at 28 days after the second MCC vaccination with concomitant administration of RotaTeq® is non-inferior to that without non-concomitant (sequential) administration of RotaTeq®.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00443846
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 3
Start date February 13, 2007
Completion date October 23, 2007
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04689191 - A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine Phase 3
Recruiting NCT04689165 - A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine Phase 3
Completed NCT00780806 - Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults Phase 1/Phase 2
Completed NCT03378258 - Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Completed NCT03205371 - Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers Phase 3
Completed NCT01352793 - A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years Phase 3
Not yet recruiting NCT06113198 - A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age Phase 4
Completed NCT03295318 - Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds Phase 2
Completed NCT03493919 - A Sourcing Study to Collect Human Blood Samples From Healthy Adults Phase 4
Completed NCT00474526 - A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants Phase 3
Completed NCT00297687 - Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults Phase 1
Recruiting NCT04665791 - A Human Controlled Infection Study With Neisseria Lactamica in Malian Adults N/A
Withdrawn NCT03431675 - Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Phase 4
Recruiting NCT02878291 - Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months Phase 1
Completed NCT00314041 - Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants Phase 2
Recruiting NCT04685850 - Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans
Completed NCT03587207 - Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years Phase 2
Completed NCT03824093 - High and Low Resource Interventions to Promote HPV Vaccines N/A
Completed NCT04707391 - Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine Phase 3
Terminated NCT00798304 - Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants Phase 2